Pharmacophore based virtual screening of cholinesterase inhibitors: search of new potential drug candidates as antialzheimer agents
Tóm tắt
Alzheimer’s disease (AD) is a distinctive medical condition characterized by loss of memory, orientation, and cognitive impairments, which is an exceptionally universal form of neurodegenerative disease. The statistical data suggested that it is the 3rd major cause of death in older persons. Butyrylcholinesterase (BChE) and acetylcholinesterase (AChE) inhibitors play a vital role in the treatment of AD. Coumarins, natural derivatives, are reported as cholinesterase inhibitors and emerges as a promising scaffold for design of ligands targeting enzymes and pathological alterations related to AD. In this regard, the 3D QSAR pharmacophore models were developed for coumarin scaffold containing BChE and AChE inhibitors. Several 3D QSAR pharmacophore models were developed with FAST, BEST, and CEASER methods, and finally, statistically robust models (based on correlation coefficient, cost value, and RMSE value) were selected for further analysis for both targets. The important features ((HBA 1, HBA 2, HY, RA (BChE) HBA 1, HBA 2, HY, PI, (AChE)) were identified for good inhibitory activity of coumarin derivatives. Finally, the selected models were applied to various database compounds to find potential BChE and AChE inhibitors, and we found 13 for BChE and 1 potent compound for AChE with an estimated activity of IC50 < 10 µM. Further, the Lipinski filters, and ADMET analysis supports the selected compounds to become a drug candidate. These selected BChE and AChE inhibitors can be used in the treatment of AD.
Tài liệu tham khảo
Abdelmohsen UR, Albohy A, Abdulrazik BS, Bayoumi SAL, Malak LG, Khallaf ISA et al (2021) Natural coumarins as potential anti-SARS-CoV-2 agents supported by docking analysis. RSC Adv 11(28):16970–16979
Abu-Aisheh MN, Al-Aboudi A, Mustafa MS, El-Abadelah MM, Ali SY, Ul-Haq Z et al (2019) Coumarin derivatives as acetyl- and butyrylcholinestrase inhibitors: an in vitro, molecular docking, and molecular dynamics simulations study. Heliyon 5(4):e01552
Alzheimer’s Association (2021) Alzhiemer’s disease facts and figures. Alzheimers Dement 11(3):332–384
Alzheimer’s disease facts and figures. Alzheimers. Dement. [Internet]. 2021;17Available from: http://www.ncbi.nlm.nih.gov/pubmed/33756057
Ambure P, Roy K (2014) Advances in quantitative structure-activity relationship models of anti-Alzheimer’s agents. Expert Opin Drug Discov 9(6):697–723
Ambure P, Bhat J, Puzyn T, Roy K (2019) Identifying natural compounds as multi-target-directed ligands against Alzheimer’s disease: an in silico approach. J Biomol Struct Dyn 37(5):1282–1306
Arya H, Coumar MS (2021) Lead identification and optimization. The design and development of novel drugs and vaccines. Elsevier, pp 31–63
Atatreh N, Al Rawashdah S, Al Neyadi SS, Abuhamdah SM, Ghattas MA (2019) Discovery of new butyrylcholinesterase inhibitors via structure-based virtual screening. J Enzyme Inhib Med Chem 34(1):1373–1379
Buran K, Reis R, Sipahi H, ÖnenBayram FE (2021) Piperazine and piperidine-substituted 7-hydroxy coumarins for the development of anti-inflammatory agents. Arch Pharm (Weinheim) 354(7):e2000354
Chadha N, Silakari O (2017) Pharmacophore based design of some multi-targeted compounds targeted against pathways of diabetic complications. J Mol Graph Model. Elsevier Inc 76:412–418
Chhabria MT, Brahmkshatriya PS, Mahajan BM, Darji UB, Shah GB (2012) Discovery of novel acyl coenzyme a: cholesterol acyltransferase inhibitors: pharmacophore-based virtual screening, synthesis and pharmacology. Chem Biol Drug Des 80(1):106–113
Contestabile A (2011) The history of the cholinergic hypothesis. Behav Brain Res 221(2):334–340
Coyle JT, Price DL, DeLong MR (1983) Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science 219(4589):1184–1190
Ellman GL, Courtney KD, Andres V, Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7(2):88–95
Fawcett T (2006) An introduction to ROC analysis. Pattern Recognit Lett 27(8):861–874
Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM (2016) Alzheimer’s disease: targeting the cholinergic system. Curr Neuropharmacol 14(1):101–115
Folch J, Petrov D, Ettcheto M, Abad S, Sánchez-López E, García ML et al (2016) Current research therapeutic strategies for Alzheimer’s disease treatment. Neural Plast 2016:8501693
Fourches D, Muratov E, Tropsha A (2010) Trust, but verify: on the importance of chemical structure curation in cheminformatics and QSAR modeling research. J Chem Inf Model 50(7):1189–1204
Francis PT (2005) The interplay of neurotransmitters in Alzheimer’s disease. CNS Spectr 10(S18):6–9
Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 66(2):137–147
Hampel H, Mesulam M-M, Cuello AC, Farlow MR, Giacobini E, Grossberg GT et al (2018) The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain 141(7):1917–1933
Healthline (2021) COVID-19, Alzheimer’s Disease, and memory loss: what we know
Heo JH, Eom BH, Ryu HW, Kang MG, Park JE, Kim DY et al (2020) Acetylcholinesterase and butyrylcholinesterase inhibitory activities of khellactone coumarin derivatives isolated from Peucedanum japonicum Thurnberg. Sci Rep. Nature Publishing Group UK 10(1):1–11
Hu YH, Yang J, Zhang Y, Liu KC, Liu T, Sun J et al (2019) Synthesis and biological evaluation of 3–(4-aminophenyl)-coumarin derivatives as potential anti-Alzheimer’s disease agents. J Enzyme Inhib Med Chem. Taylor & Francis 34(1):1083–1092
Jiang Y, Gao H (2018) Pharmacophore-based drug design for potential AChE inhibitors from Traditional Chinese Medicine Database. Bioorg Chem 76:400–414
Khedkar SA, Malde AK, Coutinho EC, Srivastava S (2007) Pharmacophore modeling in drug discovery and development: an overview. Med Chem 3(2):187–197
Lipinski CA (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44(1):235–249
Lu S-H, Wu JW, Liu H-L, Zhao J-H, Liu K-T, Chuang C-K et al (2011) The discovery of potential acetylcholinesterase inhibitors: a combination of pharmacophore modeling, virtual screening, and molecular docking studies. J Biomed Sci 18:8
Ma Y, Jin Y-Y, Wang Y-L, Wang R-L, Lu X-H, Kong D-X et al (2014) The discovery of a novel and selective inhibitor of PTP1B over TCPTP: 3D QSAR pharmacophore modeling, virtual screening, synthesis, and biological evaluation. Chem Biol Drug Des 83(6):697–709
Matthews BW (1975) Comparison of the predicted and observed secondary structure of T4 phage lysozyme. Biochim Biophys Acta - Protein Struct 405(2):442–451
Menezes JC, Diederich M (2019) Translational role of natural coumarins and their derivatives as anticancer agents. Future Med Chem 11(9):1057–1082
NIH National Institute of Aging (2021) Alzheimer’s Disease Fact Sheet
Nordberg A, Ballard C, Bullock R, Darreh-Shori T, Somogyi M (2013) A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer’s disease. Prim Care Companion CNS Disord. https://doi.org/10.4088/PCC.12r01412
Piazzi L, Cavalli A, Colizzi F, Belluti F, Bartolini M, Mancini F et al (2008) Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorganic Med Chem Lett 18(1):423–426
Pibuel MA, Díaz M, Molinari Y, Poodts D, Silvestroff L, Lompardía SL et al (2021) 4-Methylumbelliferone as a potent and selective antitumor drug on a glioblastoma model. Glycobiology 31(1):29–43
Pisani L, Catto M, De Palma A, Farina R, Cellamare S, Altomare CD (2017) Discovery of Potent dual binding site acetylcholinesterase inhibitors via homo- and heterodimerization of coumarin-based moieties. ChemMedChem 12(16):1349–1358
Rullo M, Catto M, Carrieri A, de Candia M, Altomare CD, Pisani L (2019) Chasing ChEs-MAO B Multi-Targeting 4-Aminomethyl-7-Benzyloxy-2H-Chromen-2-ones. Molecules 24(24):4507
Sliwoski G, Kothiwale S, Meiler J, Lowe EW (2014) Computational methods in drug discovery. Pharmacol Rev 66(1):334–395
Sun H (2008) Pharmacophore-based virtual screening. Curr Med Chem 15(10):1018–1024
Wang H, Yang F, Zhang S, Xin R, Sun Y (2021) Genetic and environmental factors in Alzheimer’s and Parkinson’s diseases and promising therapeutic intervention via fecal microbiota transplantation. Npj Park Dis 7(1):70
Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J (2004) Cholinesterase inhibitors used in the treatment of Alzheimer’s disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 21(7):453–478
Yang S-Y (2010) Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today 15(11–12):444–450
Yang H, Du C, Li Q, Chen T, Lu X, Li Q et al (2019a) Discovery, molecular dynamic simulation and biological evaluation of structurally diverse cholinesterase inhibitors with new scaffold through shape-based pharmacophore virtual screening. Bioorg Chem 92:103294
Yang J, Zhang P, Hu Y, Liu T, Sun J, Wang X (2019b) Synthesis and biological evaluation of 3-arylcoumarins as potential anti-Alzheimer’s disease agents. J Enzyme Inhib Med Chem 34(1):651–656
Yang X-C, Zhang P-L, Kumar KV, Li S, Geng R-X, Zhou C-H (2022) Discovery of unique thiazolidinone-conjugated coumarins as novel broad spectrum antibacterial agents. Eur J Med Chem 232:114192
Yun Y, Yang J, Miao Y, Wang X, Sun J (2020) Synthesis and biological evaluation of 4-arylcoumarins as potential anti-Alzheimer’s disease agents. Bioorg Med Chem Lett 30(4):126900